France· FR:64364739
YORVIPATH 168 microgrammes/0,56 mL, solution injectable en stylo prérempli
A palopegteriparatide product containing palopegtériparatide, registered in France by ASCENDIS PHARMA BONE DISEASES (DANEMARK), on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Palopegteriparatide is registered in 11 of 19 countries.
Countries holding a registration under ATC H05AA05 (palopegteriparatide), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 7 of them publish a price we can compare per daily dose
Palopegteriparatide · ATC H05AA05
11 / 19 countries
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- PALOPEGTÉRIPARATIDE
- Manufacturer
- ASCENDIS PHARMA BONE DISEASES (DANEMARK)
- Country
- France (FR)
- ATC code
- H05AA05
- ATC class
- Palopegteriparatide
- Defined daily dose
- 33 mcg, P
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009302889862 cartouches multidoses en verre de 0,56 mL dans 2 stylo pré-rempli + 30 aiguillesEUR 7.6
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Palopegteriparatide in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaYORVIPATHAscendis Pharma Bone Diseases A/S, Hellerup
- United StatesYorvipathAscendis Pharma, Endocrinology, Inc.
- SwitzerlandYorvipath 168 μg/0.56 ml, Injektionslösung im FertigpenAscendis Pharma Switzerland GmbH
- United KingdomYorvipath 168micrograms/0.56ml solution for injection pre-filled pensAscendis Pharma UK Ltd
- NetherlandsYorvipath 168 microgram/0,56 ml oplossing voor injectie in voorgevulde penAscendis Pharma A/S
- PolandYorvipathAscendis Pharma Bone Diseases A/S
- SwedenYorvipath 168 mikrogram/0,56 ml Injektionsvätska, lösning i förfylld injektionspennaAscendis Pharma Bone Diseases A/S
- BelgiumYorvipath 168 µg/0.56 mlAscendis Pharma Bone Diseases
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Yorvipath
- Liechtenstein · Yorvipath
- Norway · Yorvipath
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6e231ad5-2c98-4c78-a587-3193d7d25785 GET /v1/drugs/6e231ad5-2c98-4c78-a587-3193d7d25785?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "64364739",
"date_amm": "2023-11-17",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/23/1766",
"substance": "PALOPEGTÉRIPARATIDE",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable",
"voies_administration": "sous-cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about palopegteriparatide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.